Pharma BD Deal Intelligence
Illumina's $7.1B GRAIL deal became a case study in overreach: closing before EU clearance drew a EUR 432M gun-jumping fine and forced a 2024 spin-off, though the ECJ later ruled the Commission never had jurisdiction, voiding the fine entirely.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →In 2021, the American Cancer Society projects 1,898,160 new cancer cases and 608,570 cancer deaths in the United States. Five-year relative survival is 89% for…
GRAIL announced its acquisition by Illumina has closed for $7.1 billion in cash and stock, with the businesses operating separately during EU regulatory…
ECJ ruled Sept 3, 2024 that the European Commission did not have jurisdiction; the basis for the EUR 432M fine has been removed and will no longer be payable.…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Illumina closed its $7.1B acquisition of GRAIL on August 18, 2021 while EU regulatory review was still pending, gaining the Galleri multi-cancer early detection test. The premature closing triggered a multi-year antitrust fight: the European Commission prohibited the deal and in July 2023 fined Illumina EUR 432M for gun-jumping, and the US FTC litigated to unwind it. Illumina ultimately divested GRAIL via spin-off on June 24, 2024, distributing 85.5% of GRAIL shares to Illumina shareholders and retaining a 14.5% minority stake; GRAIL began trading on Nasdaq as 'GRAL' on June 25, 2024. The FTC then dismissed its case on August 15, 2024. On September 3, 2024 the European Court of Justice ruled the Commission never had jurisdiction over the deal, removing the basis for the EUR 432M fine ("no longer payable"), and the Commission withdrew its decisions on September 6, 2024. Net outcome: the acquisition was reversed and GRAIL is again an independent public company, but Illumina escaped the headline fine on jurisdictional grounds.
1.9M US cases/yr · $25.0B Projected MCED market peak (USD MM, analyst consensus) · 71 % of US cancer deaths from cancers without recommended screening
Multi-cancer early detection (MCED) addresses the diagnostic gap that 71% of US cancer deaths arise from cancers without recommended population screening (per GRAIL/PATHFINDER analyses), including pancreatic, ovarian, liver, esophageal, gastric, head & neck, and many lymphomas. Approximately 1.9 million Americans are diagnosed with cancer each year and 608,570 die of it (American Cancer Society 2021). Five-year survival is approximately 89% for cancers detected at Stage I but drops to ~21% at Stage IV, creating substantial value for shifting diagnoses to earlier stages. GRAIL's Galleri test, launched in June 2021 as a laboratory-developed test (LDT) at $949 cash-pay, uses methylation-based ctDNA sequencing on a custom 100,000-region panel to detect a cancer signal across 50+ cancer types and predict cancer signal origin (CSO) for diagnostic workup. Specificity in the CCGA Sub-Study 3 was 99.5% with overall sensitivity of 51.5% across all stages and 76.3% in Stages II-IV across the 12 'pre-specified' high-mortality cancers. The MCED market is forecast to reach $25-50 billion globally at peak per analyst estimates if Galleri-class tests achieve Medicare coverage and population uptake. Illumina's strategic logic was to vertically integrate sequencing platform + clinical test, but the deal triggered EU and FTC antitrust action ultimately forcing divestiture in 2023-2024.
The MCED competitive landscape combines methylation-based ctDNA tests, fragmentomics platforms, single-cancer liquid biopsies, and traditional single-organ screening. Methylation-based MCED: GRAIL Galleri (Illumina-acquired, methylation across 100K regions, 50+ cancers), Exact Sciences DETECT (in development under DEEP-C study), Bluestar Genomics (epigenomic methylation, pre-acquisition by Mercy BioAnalytics), Singlera Genomics (PanSeer methylation), Universal Diagnostics. Fragmentomics: Delfi Diagnostics (DELFI lung cancer, expanding to MCED), Freenome (multi-omics CRC then expansion). Multi-modal/protein+ctDNA: Thrive (CancerSEEK, acquired by Exact Sciences Jan 2021), Burning Rock (China). Single-cancer liquid biopsy with MCED extension potential: Guardant Health Shield (CRC, FDA-approved 2024), Natera Signatera (MRD), Foundation Medicine (FDA-approved CGP, expanding to MRD). Adjacent screening: Cologuard (Exact, stool DNA CRC, FDA-approved 2014), low-dose CT lung (USPSTF 2013/2021), mammography, colonoscopy, Pap/HPV cervical, PSA. The Illumina-GRAIL acquisition was challenged by FTC in March 2021 (administrative complaint) and EU Commission opened Phase II review July 2021, with Illumina closing despite EU review and ultimately divesting GRAIL via Dec 2023 spin-off.
Illumina spun off GRAIL, distributing 85.5% of shares to Illumina holders and retaining 14.5%; GRAIL (GRAL) began Nasdaq trading June 25, 2024. Reverses the 2021 acquisition under EU/FTC antitrust pressure.
European Court of Justice ruled the Commission had no jurisdiction over the deal, removing the basis for the EUR 432M gun-jumping fine ('no longer payable'). FTC had already dismissed its US case Aug 15, 2024. Commission withdrew its decisions Sept 6, 2024.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Illumina, Inc. / GRAIL, Inc. (this deal) | 2021 | $7.1B | — |
| Illumina, Inc. / Amgen Inc. | 2020 | — | 56 |
| Illumina, Inc. / GRAIL, Inc. | 2020 | $8.0B | 36 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2021 deals · Illumina, Inc. deals · Oncology deals